Patent US4447455A successfully refreshed from Google Patents.
US4447455A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Oral urolithiasis remedy
Assignee: Madaus Holding GmbH
•
Filing: 1982-08-05
•
Granted: 1984-05-08
•
Expires: 2002-08-05
Abstract
Abstract The disclosed invention deals with treating urolithiasis with alizarin. Magnesium oxide and phosphate salts may also be added.
Inventors
- 👤 Rolf Madaus
- 👤 Werner Stumpf
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 13:33
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/12; A61K33/00; A61K33/42
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
21 words
A composition for the treatment of urolithiasis comprising effective amounts of alizarin, magnesium oxide, disodium hydrogen phosphate, and potassium hydrogen phosphate.
Claim 2
Dependent Claim
21 words
A composition for the treatment of urolithiasis comprising effective amounts of alizarin, magnesium oxide, disodium hydrogen phosphate, and potassium hydrogen phosphate.
Claim 3
Dependent Claim
31 words
Composition as claimed in claim 1 comprising ______________________________________
5 to 14% alizarin,
10 to 26% magnesium oxide,
22 to 32% disodium hydrogen phosphate, and
37 to 53% potassium dihydrogen phosphate.
______________________________________
Claim 4
Dependent Claim
31 words
Composition as claimed in claim 1 in unit dosage form containing ______________________________________
35 mg alizarin,
65 mg magnesium oxide,
150 mg disodium hydrogen phosphate, and
250 mg potassium dihydrogen phosphate.
______________________________________
Claim 5
Dependent Claim
18 words
Method of treating urolithiasis, which method comprises administering to an afflicted subject a therapeutically effective amount of alizarin.
Claim 6
Dependent Claim
18 words
Method of treating urolithiasis, which method comprises administering to an afflicted subject a therapeutically effective amount of alizarin.
Claim 7
Dependent Claim
21 words
Method as claimed in claim 4 wherein a daily dosage of 140 to 500 mg is administered to the afflicted subject.
Claim 8
Dependent Claim
23 words
Method as claimed in claim 4 wherein an alizarin-containing composition is administered also containing magnesium oxide, disodium hydrogen phosphate and potassium dihydrogen phosphate.
Claim 9
Dependent Claim
33 words
Method as claimed in claim 6 wherein an alizarin-containing composition is administered containing ______________________________________
10 to 26% magnesium oxide
22 to 32% disodium hydrogen phosphate, and
37 to 53% potassium dihydrogen phosphate.
______________________________________
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-05-08 | 1987-11-07 | 1988-05-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-05-08 | 1991-11-07 | 1992-05-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-05-08 | 1995-11-07 | 1996-05-08 | $7700.00 | Window Closed / Lapsed |